Dispatches from Jefferies: Why Alkermes wants Avadel, Light Chain’s hope for CD47, and morenews2025-11-20T16:33:02+00:00November 20th, 2025|Endpoints News|
AbbVie, Novartis can proceed with legal fight against Utah 340B lawnews2025-11-20T15:40:44+00:00November 20th, 2025|Endpoints News|
FDA will allow email ‘clarifications’ after pharma company meetingsnews2025-11-20T14:34:56+00:00November 20th, 2025|Endpoints News|
Flagship and portfolio companies do deals with GSK, Merck KGaA and Saudi Arabianews2025-11-20T14:27:08+00:00November 20th, 2025|Endpoints News|
FDA approves new indication and monthly dose of Regeneron’s Eylea HDnews2025-11-20T14:14:22+00:00November 20th, 2025|Endpoints News|
Post-Hoc Live: The drug industry’s Mr. Reality Check, Derek Lowenews2025-11-20T12:00:14+00:00November 20th, 2025|Endpoints News|
Novartis raises the sales bar for key cancer drugs, tweaks yearly growth guidancenews2025-11-20T11:43:02+00:00November 20th, 2025|Endpoints News|
FDA approves Bayer’s HER2-mutated lung cancer drugnews2025-11-19T20:28:57+00:00November 19th, 2025|Endpoints News|
Pfizer CFO says drugmaker will ‘supplement’ Metsera deal as part of broader obesity ambitionsnews2025-11-19T19:27:38+00:00November 19th, 2025|Endpoints News|
Life sciences sector ‘has lost confidence’ in the UK, committee member saysnews2025-11-19T18:59:22+00:00November 19th, 2025|Endpoints News|
